ArticlesINTRAOCULAR BEVACIZUMAB FOR IRIS NEOVASCULARIZATION IN A SILICONE OIL–FILLED EYESingh, Ajay MBBS, MS; Stewart, Jay M. MDAuthor Information From the Department of Ophthalmology, University of California at San Francisco, San Francisco, California. Supported by an unrestricted grant from Research to Prevent Blindness, Inc. A. S. is a Hearst Fellow. The authors have no commercial interests related to the material presented in this report. Reprint requests: Jay M. Stewart, MD, Department of Ophthalmology, University of California at San Francisco, 10 Koret Way, K301, San Francisco, CA 94143-0730; e-mail: [email protected] Retinal Cases & Brief Reports: Summer 2008 - Volume 2 - Issue 3 - p 253-255 doi: 10.1097/ICB.0b013e31816ddb86 Buy Metrics AbstractIn Brief Purpose: To report the effectiveness of intravitreal injection of bevacizumab for treatment of iris neovascularization in a silicone oil–filled eye. Design: Case report. Patient: A 56-year-old man with recurrent retinal detachment associated with iris neovascularization. Results: Iris neovascularization regressed after treatment with a 1.25-mg intravitreal injection of bevacizumab in the presence of silicone oil. Discussion: Intraocular injection of bevacizumab is an effective short-term treatment of neovascularization caused by persistent retinal detachment even in the presence of silicone oil. The standard dose of 1.25 mg of bevacizumab may not require adjustment in an aphakic vitrectomized eye. Intravitreal injection of bevacizumab was found to be effective in treating anterior segment neovascularization in an eye with silicone oil. © 2008 Ophthalmic Communications Society, Inc.